Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Is PTCy Linked with Donor Derived Malignancy?

Biol Blood Marrow Transplant; ePub 2017 Jan 3; Majzner, et al

Publish date:: January 11, 2017

The estimated cumulative incidence of donor derived malignancy after post-transplant cyclophosphamide (PTCy 0.5%) in 789 individuals was at or below the rate of such found in the published literature.

Participants underwent allogeneic transplant and received PTCy at the Johns Hopkins Hospital between 2000 and 2011.

Investigators saw 4 cases of donor derived malignancy, which they noted is similar to or below the rate seen in published studies.

Citation:

Majzner R, Mogri H, Varadhan R, et al. Post-transplant cyclophosphamide after bone marrow transplantation is not associated with an increased risk of donor derived malignancy. [Published online ahead of print January 3, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2016.12.640.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Cellular Therapy

CAR T-cell therapy may worsen mental health in some patients,

New Toxicity Subscale Measures QOL in Cancer Patients on Checkpoint Inhibitors,

CAR T cells produce complete responses in T-cell malignancies,

CAR T-cell therapy advances in CLL,

Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients,